1-8 of 8
Tara J Masterson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Carolina Schinke, Gareth Morgan, Luciano J. Costa, Natalie Callander, Don A. Stevens, Jesus G Berdeja, Brea Lipe, Sagar Lonial, Marie-Christiane Vekemans, Ravi Vij, Philippe Moreau, Paula Rodríguez-Otero, Anna Sureda Balari, Thomas Renaud, Jaszianne Tolbert, Bonnie W Lau, Brandi W Hilder, Tara J Masterson, Michela Campagna, Veronique Vreys, Christoph Heuck, Colleen Kane, Kathleen S Gray, Deeksha Vishwamitra, Indrajeet Singh, Joy Gong, Xiang Qin, Larysa Sanchez
Journal: Blood
Blood (2024) 144 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2024-199797
Published: 2024
Journal Articles

Efficacy and Safety of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study

Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Hideto Tamura, Mikihiro Takamoto, Hiroshi Yamazaki, Ei Fujikawa, Lixia Pei, Tara J Masterson, Michela Campagna, Bonnie W Lau, Yasushi Takamatsu
Journal: Blood
Blood (2024) 144 (Supplement 1): 7011.
https://doi.org/10.1182/blood-2024-199663
Published: 2024
Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 4757.1.
https://doi.org/10.1182/blood-2024-199752
Published: 2024
Journal Articles

Mechanisms of Resistance and Relapse with Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 MonumenTAL-1 Study

Deeksha Vishwamitra, Sheri Skerget, Diana Cortes, Onsay Lau, Cuc Davis, Thomas Renaud, Jaszianne Tolbert, Brandi W Hilder, Tara J Masterson, Michela Campagna, Christoph Heuck, Ajai Chari, Niels WCJ van de Donk, Raluca Verona
Journal: Blood
Blood (2023) 142 (Supplement 1): 1933.
https://doi.org/10.1182/blood-2023-187755
Published: 2023
Journal Articles

Symptoms, Functioning, and Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab: Updated Patient-Reported Outcomes from the Phase 1/2 MonumenTAL-1 Study

Carolina Schinke, Cyrille Touzeau, Albert Oriol, María-Victoria Mateos, Don A. Stevens, Leo Rasche, Xiang Qin, Kelly Kato, Timothy Ming, Eva G Katz, Katharine S Gries, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Philippe Moreau, Jesús San-Miguel, Paula Rodríguez Otero, Ajai Chari
Journal: Blood
Blood (2023) 142 (Supplement 1): 6711.
https://doi.org/10.1182/blood-2023-189151
Published: 2023
Journal Articles

Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

Ajai Chari, Albert Oriol, Amrita Krishnan, Maria Del Carmen Martinez Chamorro, Luciano Costa, Maria Victoria Mateos, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, M. Damiette Smit, Swarna Ramanjulu, Paula Rodríguez Otero
Journal: Blood
Blood (2023) 142 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2023-181228
Published: 2023
Journal Articles

Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study

Larysa Sanchez, Carolina Schinke, Amrita Krishnan, Jésus G Berdeja, Niels WCJ van de Donk, María Victoria Mateos, Ajai Chari, Samir Parekh, Tarek H. Mouhieddine, Sundar Jagannath, Nizar J Bahlis, Cyrille Touzeau, Albert Oriol, Jesus San-Miguel, Paula Rodriguez Otero, Monique C Minnema, Michela Campagna, Tara J Masterson, Brandi W Hilder, Jaszianne Tolbert, Thomas Renaud, Kathleen Gray, Damiette Smit, Christoph Heuck, Leo Rasche
Journal: Blood
Blood (2023) 142 (Supplement 1): 2007.
https://doi.org/10.1182/blood-2023-182330
Published: 2023
Journal Articles

Updated Results of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma with Prior Exposure to T-Cell Redirecting Therapies: Results of the Phase 1/2 MonumenTAL-1 Study

Andrzej J Jakubowiak, Sebastien Anguille, Lionel Karlin, Ajai Chari, Carolina Schinke, Leo Rasche, Jesus San-Miguel, Michela Campagna, Brandi W Hilder, Tara J Masterson, Xiang Qin, Thomas Renaud, Jaszianne Tolbert, Deeksha Vishwamitra, Sheri Skerget, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 3377.
https://doi.org/10.1182/blood-2023-187242
Published: 2023